FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune peripheral nervous system disorder with limited treatment options.
• FTY720, an S1P receptor agonist, has shown promise in experimental autoimmune neuritis (EAN).

Purpose of the Study:

• To investigate the efficacy of FTY720 in chronic experimental autoimmune neuritis (c-EAN), a rat model of human CIDP.
• To evaluate FTY720's immunomodulatory effects on inflammatory cell infiltration and cytokine profiles in c-EAN.

Main Methods:

• c-EAN was induced in Lewis rats using S-palm P0(180-199) peptide immunization.
• Rats received daily FTY720 (1 mg/kg) or vehicle treatment from clinical onset for 18 days.
• Clinical signs, electrophysiology, histology, and serum cytokine levels were assessed up to 60 days post-immunization.

Main Results:

• FTY720 significantly decreased c-EAN severity and abolished disease chronicity.
• Treatment reversed electrophysiological and histological abnormalities, preserving myelinated fibers.
• FTY720 inhibited macrophage and IL-17+ cell infiltration and reduced pro-inflammatory cytokines.

Conclusions:

• FTY720 demonstrates beneficial effects in the c-EAN model, mimicking human CIDP.
• FTY720 acts as an effective immunomodulatory agent, improving disease course and preserving nerve integrity.
• These findings support further investigation of FTY720 and S1P pathway modulators for human peripheral neuropathies.